Trends in Pharmacological Sciences
ReviewRole of the renin–angiotensin system in vascular inflammation
Introduction
The renin–angiotensin system (RAS) plays a key role in the development and pathophysiology of hypertension and cardiovascular disease (CVD). In hypertension small and large arteries undergo structural, mechanical and functional changes that contribute to vascular complications and increased cardiovascular risk. Growing evidence indicates that hypertension-induced vascular injury involves a low-grade inflammatory process and that inflammation plays a significant role in the pathophysiology of high blood pressure (BP) and its complications [1]. Inflammation is a complex process that can arise in tissues in response to pathogenic stimuli. Usually, inflammation leads to recovery and restoration of tissue integrity, but if repair is imperfectly controlled the inflammatory process could result in persistent tissue damage. Angiotensin (Ang) II, a potent vasoactive peptide and the main effector of the RAS, induces vascular remodeling and endothelial dysfunction in association with increases in levels of BP. However, Ang II is able to induce vascular injury independently of its haemodynamic effects [2]. BP-independent vascular injury induced by Ang II can be explained, at least in part, by its proinflammatory properties (Figure 1). The present review discusses recent findings regarding the pathophysiology of vascular inflammation in hypertension, focusing specifically on the role of Ang II and the clinical implications and new therapeutic possibilities for CVDs thereof.
Section snippets
RAS and vascular inflammation
Independently of the etiology of the primary stimulus and the tissue involved, inflammation classically follows three stages: increased vascular permeability, leukocyte recruitment and activation of tissue-repair processes. Ang II influences all the stages of the inflammatory response (Figure 2).
Molecular mechanisms involved in RAS-induced vascular inflammation
Among the intracellular signaling pathways involved in Ang-II-induced vascular remodeling and inflammation, the production of ROS and the activation of proinflammatory transcription factors such as nuclear factor (NF)-κB play a key role (Figure 3).
Molecular mechanisms that antagonize RAS-induced vascular inflammation
Effects of Ang II can be counteracted by some mechanisms, and among these we should mention peroxisome proliferator activated receptors (PPARs). PPARs are nuclear receptors that in the inactivated state are bound to corepressor proteins. Under the effect of PPAR activators, they dissociate from their corepressors and recruit coactivators, including a PPAR-binding protein and the steroid receptor coactivator-1, and then bind to a PPAR response element (PPRE) in target genes to modulate gene
Role of aldosterone and other components of the RAS in Ang-II-induced vascular inflammation
Aldosterone is a mineralocorticoid hormone produced by the adrenal glomerulosa whose secretion is regulated by different agents, the most important of which is Ang II. It plays a key role in hypertension and CVDs, beyond its effects on the kidney to retain salt and water, by contributing to vascular inflammation, oxidative stress, fibrosis and the vascular injury [64]. Aldosterone, through activation of the mineralocorticoid receptor (MR), caused vascular injury in brain, heart and kidneys by
Clinical implications of vascular inflammation in hypertension
Considering that, as described hitherto, inflammation plays a key role in the pathophysiology of Ang-II-induced vascular injury, it is relevant to consider the impact of these data on clinical practice. Biomarkers of systemic low-grade inflammation predict incident hypertension and cardiovascular risk 70, 71. Several mediators of inflammation, including C-reactive protein (CRP), myeloperoxidase (MPO), IL-1, IL-6, IL-18, TNF-α, soluble adhesion molecules (sICAM, sVCAM, sE-selectin, P-selectin),
Conclusions
Inflammation and the RAS are intricately interrelated and their association induces an amplification process that involves oxidative stress and proinflammatory transcription factors, leading to progressive vascular injury in hypertension. A growing body of evidence also suggests that inflammation through vascular remodeling participates in the mechanisms leading to the development and pathophysiology of hypertension and its complications, which could mean that inflammatory mediators could be
Acknowledgements
The work of the authors was supported by Canadian Institutes of Health Research grants 37917 and 82790, a Canada Research Chair on Hypertension and Vascular Research and the Canadian Fund for Innovation, all to E.L.S.
References (74)
Inflammation and angiotensin II
Int. J. Biochem. Cell Biol.
(2003)Direct evidence of leukocyte adhesion in arterioles by angiotensin II
Blood
(2004)The multiple actions of angiotensin II in atherosclerosis
Regul. Pept.
(2000)A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles
Blood
(2007)Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT1 receptor blockade in hyperlipidemic rabbits
Biochem. Biophys. Res. Commun.
(2001)Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis
J. Am. Coll. Cardiol.
(2001)Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease
J. Am. Coll. Cardiol.
(2004)Angiotensin II differentially regulates interleukin-1-β-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK
J. Biol. Chem.
(2004)NF-κB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells
J. Mol. Cell. Cardiol.
(2002)Vascular endothelin in hypertension
Vascul. Pharmacol.
(2005)
Preconditioning protects endothelium by preventing ET-1-induced activation of NADPH oxidase and xanthine oxidase in post-ischemic heart
J. Mol. Cell. Cardiol.
Renin-angiotensin system and cardiovascular risk
Lancet
Inflammation in hypertension
Curr. Opin. Nephrol. Hypertens.
Beyond blood pressure: the endothelium and atherosclerosis progression
Am. J. Hypertens.
Cyclooxygenase-2 and the renal renin-angiotensin system
Acta Physiol. Scand.
Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling
Hypertension
Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT1 and AT2 receptor-mediated P-selectin upregulation
Circulation
Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II
Curr. Opin. Nephrol. Hypertens.
Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines
J. Immunol.
Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells
Hypertension
Genes overexpressed in cerebral arteries following salt-induced hypertensive disease are regulated by angiotensin II, JunB, and CREB
Am. J. Physiol. Heart Circ. Physiol.
Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines
Circulation
CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration
Arterioscler. Thromb. Vasc. Biol.
Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury
Arterioscler. Thromb. Vasc. Biol.
Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction
J. Exp. Med.
Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan
J. Cardiovasc. Pharmacol.
Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
Circulation
Anti-inflammatory and metabolic effects of candesartan in hypertensive patients
Int. J. Cardiol.
Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors
J. Thromb. Thrombolysis
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis
Front. Biosci.
Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries
Hypertension
Essential role of Smad3 in angiotensin II-induced vascular fibrosis
Circ. Res.
Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism
Circulation
Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis
Circulation
ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo
Am. J. Physiol. Heart Circ. Physiol.
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity
Circulation
Role of matrix metalloproteinases in early hypertensive vascular remodeling
Hypertension
Cited by (366)
Possible role of metformin as an antidepressant in diabetes
2024, Journal of Affective DisordersTelmisartan loading thermosensitive hydrogel repairs gut epithelial barrier for alleviating inflammatory bowel disease
2024, Colloids and Surfaces B: BiointerfacesThymus vulgaris, a natural pharmacy against COVID-19: A molecular review
2023, Journal of Herbal MedicineLipid mediators generated by the cytochrome P450—Epoxide hydrolase pathway
2023, Advances in PharmacologyCardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
2022, Molecular MetabolismCitation Excerpt :RAS plays a key role in the development of hypertension and CVD which is mediated, to a great extent, by the pro-inflammatory effects of AngII signalling pathway [213]. Initially, AngII sets the stage for the inflammatory process by enhancing vascular permeability through increasing BP or by releasing prostaglandins and vascular endothelial growth factors [214]. Subsequently, the role of AngII in leucocyte recruitment to the vascular wall comes into play.